VVOS logo

VVOS
Vivos Therapeutics Inc

5,435
Mkt Cap
$8.13M
Volume
112,465.00
52W High
$7.95
52W Low
$0.545
PE Ratio
-0.25
VVOS Fundamentals
Price
$0.6199
Prev Close
$0.5848
Open
$0.599
50D MA
$1.00
Beta
0.83
Avg. Volume
401,147.96
EPS (Annual)
-$2.06
P/B
-6.93
Rev/Employee
$65,085.82
$32.27
Loading...
Loading...
News
all
press releases
Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates
Plus (PSTV) delivered earnings and revenue surprises of -11.11% and +8.21%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
More News
News Placeholder
Vivos Therapeutics Inc Full Year Sales Increase
(RTTNews) - Vivos Therapeutics Inc (VVOS) released Loss for full year of -$21.17 million...
News Placeholder
Broadcom, Vivos Therapeutics And 3 Stocks To Watch Heading Into Monday
U.S. stocks mixed, Cheer Holding announces reverse stock split, Vivos Therapeutics gains investor stake, Quhuo Ltd. reports loss.read more...
News Placeholder
Insider Buying: Vivos Therapeutics (NASDAQ:VVOS) Major Shareholder Buys 1,353,625 Shares of Stock
Vivos Therapeutics, Inc. (NASDAQ:VVOS - Get Free Report) major shareholder Michael Skaff purchased 1,353,625 shares of the business's stock in a transaction on Tuesday, March 31st. The stock was...
News Placeholder
Why Did Vivos Therapeutics (VVOS) Stock Jump Over 21% After Hours
Vivos Therapeutics shares surge 21.21% after hours as a Michigan-based investor group acquires a 19.9% stake through a $2.39 million private placement.read more...
News Placeholder
NRx Pharmaceuticals, Inc. (NRXP) Surpasses Q4 Earnings Estimates
NRx Pharmaceuticals (NRXP) delivered earnings and revenue surprises of +323.53% and -84.40%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Theravance Biopharma (TBPH) Q4 Earnings and Revenues Lag Estimates
Theravance Bio (TBPH) delivered earnings and revenue surprises of -86.47% and -23.28%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Health Catalyst (HCAT) Lags Q4 Earnings Estimates
Health Catalyst (HCAT) delivered earnings and revenue surprises of -14.26% and +1.45%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Rigel Pharmaceuticals (RIGL) Q4 Earnings Miss Estimates
Rigel (RIGL) delivered earnings and revenue surprises of -14.29% and 0.00%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Vivos Therapeutics (VVOS) Upgraded to Buy: Here's What You Should Know
Vivos Therapeutics (VVOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available